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S U M M A R Y
Objectives: To determine the incidence and laboratory characteristics of primary Toxoplasma gondii
infection in HIV-infected individuals.
Methods: This retrospective study was conducted between 1988 and 2012 on a cohort of 1130 HIV-
infected patients at the AIDS Center Prague. Toxoplasma serology, standard laboratory parameters, and
health status were evaluated at 3–6-month intervals for all patients.
Results: The total person-time of follow-up of patients at risk of Toxoplasma seroconversion was 3046.3
years; there were 14 primary T. gondii infections, yielding an incidence rate of 0.0046 (95% conﬁdence
interval 0.0027–0.0078). Most of the subjects were clinically asymptomatic, but in one case
seroconversion was accompanied by transient cervical lymphadenopathy. The CD4+ T-lymphocyte
count geometric mean increased from 418 (95% conﬁdence interval 303–579) cells/ml before
seroconversion to 501 (95% conﬁdence interval 363–691) cells/ml after seroconversion (p = 0.004),
while other parameters (CD8+ T-lymphocytes, natural killer cells, viral load, beta2-microglobulin, total
immunoglobulins) remained unchanged. As compared to the control group, patients with primary
toxoplasmosis had higher initial levels of total immunoglobulins IgA and IgG and a tendency to higher
CD8+ T lymphocyte counts.
Conclusions: Neither the incidence nor the course of the primary Toxoplasma infection was inﬂuenced
by the immune status of the patients. Immune parameters of patients with primary Toxoplasma
infection did not differ from those of the controls.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Toxoplasmosis caused by the protozoon Toxoplasma gondii
(Apicomplexa) is one of the most common widespread parasitic
diseases worldwide and is one of the major opportunistic
infections afﬂicting patients with advanced HIV infection. The
primary infection in immunocompetent individuals, which is
asymptomatic or accompanied by mild and non-speciﬁc symp-
toms in most cases, is usually followed by a lifelong latent
infection. Any subsequent reactivation of latent toxoplasmosis due
to severe immunodeﬁciency is manifested most often as cerebral
toxoplasmosis. Since the mid-1980s this disease has been the focus
of greatly increased attention and the circumstances of its
pathogenesis and clinical and laboratory symptoms are relatively
well known, whilst effective therapy and prophylaxis are* Corresponding author. Tel.: +420 606 111380; fax: +420 2 66082629.
E-mail addresses: ladimachala@centrum.cz, ladimachala@hotmail.com
(L. Machala).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.03.017available.1 Nonetheless, little is known about the incidence and
manifestations of primary T. gondii infection in HIV-infected
individuals.2
For this reason we decided to carry out a retrospective analysis
of medical records pertaining to HIV-infected patients at the AIDS
Center Prague in order to determine the incidence and laboratory
and clinical characteristics of primary T. gondii infection. In this
health care setting, a total of 1130 HIV-infected patients are
followed up, representing approximately 65% of all diagnosed HIV-
infected patients in the Czech Republic.3 This study was possible
thanks to many years of close cooperation between the AIDS
Center at the Bulovka Hospital in Prague and the National
Reference Laboratory for Toxoplasmosis at the National Institute
of Public Health in Prague.
2. Methods
All HIV-infected patients attending the AIDS Center at Bulovka
Hospital in Prague between November 1988 and April 2012 were
included in this retrospective study. Blood samples were collectedses. Published by Elsevier Ltd. All rights reserved.
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for testing T. gondii serology as well as immunological, hemato-
logical, and biochemical parameters. Throughout the study,
complement ﬁxation tests (CFT), IgG ELISA, and IgM ELISA were
used for the detection of anti-Toxoplasma antibodies. According to
the manufacturer’s information, TestLine Toxoplasma diagnostic
kits show the following sensitivity/speciﬁcity: CFT 97–99%/95–
98%, ELISA IgG 98.9%/99.2%, and ELISA IgM 96.4%/97.9%.4–7 CFT
titers 1:8 were considered positive. The Toxoplasma status of
patients whose test results ﬂuctuated during follow-up was
considered negative when the initial sample was negative and
no more than one positive result was detected thereafter; the
Toxoplasma status was considered positive when the initial
sample was positive and repeated (twice or more) positive
samples were detected. Seroconversions were detected by
follow-up of patients if the initial (at least two) negative samples
were followed by an uninterrupted sequence of samples positive
both by CFT and ELISA IgG. The dynamics of the antibody response
were monitored. Patients were classiﬁed retrospectively into
groups according to their T. gondii infection status as recorded at
serological follow-ups.
Other monitored laboratory markers included the HIV RNA viral
load measured by PCR (limit of detection 20 copies/ml) and
parameters of both humoral immunity (serum immunoglobulins
IgG (normal range 7.51–15.6 g/l), IgM (normal range 0.46–3.04 g/l)
and IgA (normal range 0.82–4.53 g/l), and beta2-microglobulin
(normal range 0.7–1.8 mg/l)) and cellular immunity (such as
numbers of natural killer cells (NK; normal range 300–700/ml),
CD4+ T lymphocytes (CD4; normal range 700–1100/ml), and CD8+
T lymphocytes (CD8; normal range 500–900/ml) tested by ﬂow
cytometry and also levels of serum C-reactive protein (normal
range 0–8 mg/l)).
The clinical status of all patients was examined at the AIDS
Center every 3–6 months and it was noted whether these patients
were receiving combination antiretroviral therapy (cART) or anti-
Toxoplasma prophylaxis. In the case of seroconversion, the medical
records were retrospectively reviewed for possible clinical
symptoms during the previous 12 weeks and patients were
additionally interviewed for the same information.
The study was approved by the local ethics committee of
Bulovka Hospital and was conducted in accordance with the
ethical standards laid down in the 1975 Declaration of Helsinki. All
patients agreed to participate in the study and signed an informed
consent.
2.1. Statistical analysis
Model-based geometric means together with corresponding
95% conﬁdence intervals (95% CI) were calculated to characterize
the central tendency and variability of the analyzed variables in the
groups. Within-group and between-group comparisons were
based on a mixed-effects linear regression model with random
intercepts ﬁtted via maximum likelihood.
For comparison of the basic characteristics of patients with
anti-Toxoplasma seroconversion with patients without toxoplas-
mosis, a control group of 56 individually matched Toxoplasma-
negative patients (four controls per case) was randomly selected
from the cohort. Controls were matched to cases on year of HIV
diagnosis (3 years), age at HIV diagnosis (7 years), gender, and, if
possible, also by transmission route of HIV infection. It was required
that each control patient had negative Toxoplasma tests on at least
four different days. For comparison, the clinical data of cases at 1 year
pre-seroconversion and 1 year post-seroconversion were used. For
the controls, we used the data covering an equivalent time period as
that found in matched patients before seroconversion. All controls
during this period were asymptomatic for HIV.The anticipated time of the seroconversion was determined as
the middle of the time interval between the last negative and the
ﬁrst positive serology. The incidence rate of T. gondii in HIV-
infected patients was calculated from the total follow-up time of
Toxoplasma-negative persons and the number of seroconversion
cases.
Tests of categorical variables were based on Fisher’s exact test
and its generalization.
All statistical tests were treated as two-sided, and results with
p-values less than 0.05 were considered statistically signiﬁcant.
The data were analyzed with a Stata software package, version 9.2
(Stata Corporation, College Station, TX, USA).
3. Results
A total of 1130 patients – 956 males (mean age at HIV diagnosis
33.7 years) and 174 females (mean age at HIV diagnosis 28.1 years)
– were evaluated in the study, representing 5530.8 person-years of
follow-up time. The median follow-up period of repeatedly tested
patients with 2–49 samples was 3.2 years; the maximum follow-
up was 22.4 years.
As evident from positive CFT and ELISA IgG results, 396 (41.4%)
males and 78 (44.8%) females were infected with T. gondii before
diagnosis of the HIV infection. In total, 642 seronegative patients
(550 (57.5%) males and 92 (52.9%) females) had no change in their
negative status during the whole follow-up time.
Seroconversion indicating a recent T. gondii infection was
observed in 14 patients (10 (1.0%) males and four (2.3%) females).
The total person-time of follow-up of HIV-infected patients at risk
of Toxoplasma seroconversion was 3046.3 years. The resulting
incidence rate of primary toxoplasmosis in the cohort was
therefore 0.0046 with a 95% conﬁdence interval of 0.0027–
0.0078. The age of patients with observed seroconversion was
22–63 years (median 44 years) in males and 24–33 years (median
27 years) in females, and the interval of follow-up after diagnosis of
HIV was 0–11 years (median 4.2 years).
Among patients with a recent T. gondii primary infection, the
highest CFT titers did not exceed 1:32 in seven cases; one patient
reached a maximum titer of 1:64. Higher CFT titers (1:128–1:4096)
occurred in six cases, although only in three of the cases was the
positive CFT accompanied by positive anti-Toxoplasma IgM in the
ELISA test (Table 1). IgA ELISA antibodies were detected in two
cases only (patients 3 and 6).
The mean CD4 count in patients with seroconversion was 479
(range 93–1197) cells/ml and seven patients were on cART
consisting of one protease inhibitor boosted with ritonavir and
two nucleoside reverse transcriptase inhibitors. In the majority of
cases the seroconversion was not accompanied by clinical
symptoms with possible relevance to primary T. gondii infection.
Only one patient (patient 5), a pregnant woman with a CD4 count
of 663 cells/ml, had a diagnosis of cervical lymphadenopathy
lasting for 3 weeks. None of the patients with observed
seroconversion were taking any anti-Toxoplasma prophylactic
regimen.
The values of all monitored immunological parameters differed
substantially between patients (Table 1). Comparison of mean
values of monitored parameters pre-seroconversion and post-
seroconversion revealed a signiﬁcant increase in CD4 counts
following infection by Toxoplasma (Table 2). No signiﬁcant
differences were detected for any of the other parameters.
Comparison with the control group (Table 2) showed that
Toxoplasma seroconversion was preceded by increased CD8 values
(p = 0.062) and total IgG, IgA (both p < 0.001), and IgM (p = 0.056).
For the other monitored parameters, no signiﬁcant differences
between groups were observed.
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Primary T. gondii infection is usually asymptomatic and often
occurs before adulthood. Detection of its incidence therefore
requires large longitudinal cohort studies on anti-Toxoplasma-
negative individuals, and hence only limited data about the
incidence of primary T. gondii infection in HIV-infected patients are
available from literature sources. In our cohort, the majority of
patients (97.5% males and 95.1% females) acquired toxoplasmosis
before the diagnosis of HIV infection.
A recent primary T. gondii infection was observed in only 1.2% of
monitored individuals and the incidence was 0.0046 cases per
person-year at risk. These values are consistent with the annual
rise in the infection rate (0.0041) observed in German HIV-infected
patients, but are signiﬁcantly lower than the rate of 0.0163 per
person-year determined in the SEROCO–HEMOCO study from
France.2,8 Two other French studies also showed higher incidence
rates. Derouin at al.9 observed an annual rate of seroconversion of
0.01, and in the study of Candolﬁ et al. the annual rate was 0.023.10
This higher incidence in France apparently reﬂects a different
epidemiological situation and can also be illustrated by the higher
incidence of toxoplasmosis in pregnant French women. In a study
by Ancelle et al.,11 a toxoplasmosis incidence of 0.0148 per
susceptible pregnancy was found, whereas in Central European
countries it was markedly lower: in the Czech Republic 0.0023
cases per pregnancy and in Austria and Germany analogous rates
were 0.005 and 0.007, respectively.12–14 In Poland, the estimated
incidence of acquired infection during pregnancy was 0.005 per
pregnancy.15
CFT seroconversion was detected simultaneously with positive
IgM levels in only four out of 14 cases of primary T. gondii infection;
these IgM levels are considered as determinative markers of recent
T. gondii infection. Our data do not reveal any direct association
between maximum CFT titers and mean CD4, CD8, or NK cell
counts in patients. The possible explanation for the weakened
serological response is likely to be found in residual immune
dysregulation affecting T and B cell quantities and functions,
immune activation, or immunosenescence.16,17 Likewise, the
elevated levels of immunoglobulin IgA, IgG, and IgM against
controls, which we detected in patients prior to seroconversion,
may have a similar root cause. One study on HIV-infected subjects
correlated production of speciﬁc antibodies with the increase in
interleukin (IL)-21 levels and IL-21-R-expressing B cells.18
Unfortunately, neither in our study, nor in other published studies,
were these markers tested.
In some studies, increased serum beta2-microglobulin is cited
as a reliable marker of fetal T. gondii infection.19,20 In contrast, our
ﬁndings did not conﬁrm elevated levels of serum beta2-micro-
globulin in HIV-infected adult individuals recently infected with T.
gondii. Likewise, we did not conﬁrm the statistically signiﬁcant
association between T. gondii infection and elevated CRP found in
the study of Birgisdo´ttir et al.21
Clinical follow-up of the patients showed that in all but one case
(patient 5 with transient cervical lymphadenopathy) seroconver-
sion was not accompanied by clinical symptoms. This is similar to
the situation in normal immunocompetent individuals, in whom
more than 90% of primary T. gondii infections are asymptomatic
and cervical lymphadenopathy is the most common manifestation
of a symptomatic course.22 None of the cases of cerebral
toxoplasmosis in our cohort recorded since 1988 occurred in
patients who acquired the disease during the course of monitoring.
Similarly, none of the six HIV-infected patients with toxoplasmosis
seroconversion described by Reiter-Owona et al.2 had conﬁrmed
cerebral toxoplasmosis. Likewise, in the SEROCO and HEMOCO
cohorts, none of the 14 cases with seroconversion were accompa-
nied by clinical manifestations.8
Table 2
Immunological and virological parameters of HIV-infected patients before and after Toxoplasma seroconversion in comparison with a control group of matched HIV-positive
Toxoplasma-negative individuals. Geometric means for cases with seroconversion are calculated for the period of 1 year before and 1 year after seroconversion. For the
controls, we used an equivalent time period as that found in matched patients before seroconversion
Parameter Cases before seroconversion Cases after seroconversion Controls
Geometric mean 95% CI Geometric mean 95% CI p-Valuea Geometric mean 95% CI p-Valueb
CD4+T cells/ml 418 (303, 579) 501 (363, 691) 0.004 479 (418, 549) 0.282
CD8+T cells/ml 1217 (900, 1646) 1336 (991, 1803) 0.262 1106 (1011, 1210) 0.062
NK cells/ml 226 (142, 359) 217 (137, 343) 0.598 260 (228, 297) 0.212
HIV RNA (copies/ml) 336 (47, 2392) 167 (24, 1155) 0.365 103 (36, 292) 0.317
beta2-microglobulin (mg/l) 2.2 (1.9, 2.5) 2.5 (2.1, 2.9) 0.101 2.2 (1.9, 2.5) 0.654
CRP (mg/l) 2.1 (1.4, 3.1) 2.4 (1.4, 4.0) 0.787 2.2 (1.7, 2.7) 0.117
IgA total 3.5 (2.8, 4.5) 3.8 (3.0, 4.8) 0.245 2.6 (2.3, 2.9) <0.001
IgG total 17.4 (14.5, 20.9) 19.1 (15.9, 23.0) 0.153 14.4 (13.3, 15.7) <0.001
IgM total 1.4 (1.0, 2.1) 1.4 (0.9, 2.0) 0.632 1.1 (1.0, 1.3) 0.056
CI, conﬁdence interval; NK, natural killer; CRP, C-reactive protein.
a Paired comparison of cases before and after seroconversion.
b Two-sample comparison of cases before seroconversion to controls.
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was not associated with the state of T-cell-mediated immunity. For
reactivation of latent T. gondii infection a CD4 count of <100 cells/
ml is generally considered as critical.23,24 The mean CD4 count of
479 cells/ml in our patients was signiﬁcantly higher, but even in
the only case with a CD4 count below 100 cells/ml (patient 12 with
a CD4 count of 93 cells/ml) no clinical signs of primary T. gondii
infection were observed. More than half of our patients had an NK
count below the lower limit, but none of them had any symptoms
of primary T. gondii infection.
It is known that for host resistance to T. gondii, the production of
interferon-gamma by innate-type NK cells, which are responsible
for the initial control of parasite growth, and later by adaptive CD4
and CD8, is crucial.25–27 It might therefore be expected that
individuals with deﬁcits in these key immune cells could be more
susceptible to T. gondii infection and thus prevail among the
persons who acquire the infection. However, our ﬁndings do not
conﬁrm this hypothesis. The CD4 and NK counts in the HIV-
infected patients before primary T. gondii infection did not
signiﬁcantly differ from the counts in the control group patients,
who remained Toxoplasma-negative. An unexpected ﬁnding,
which is difﬁcult to explain, is the higher CD8 count before
Toxoplasma seroconversion. This increase, similar to the elevation
of IgA, IgG, and IgM levels against the control values that we
recorded in patients prior to seroconversion, can hardly be
associated with higher susceptibility to T. gondii infection and it
may be a manifestation of an imbalance in the cellular response
caused by the HIV infection. On the other hand, treatment, which
can signiﬁcantly improve the patient’s immune status, did not
prevent infection – both the treated and untreated patients
became infected with Toxoplasma.28 Evidently, other factors such
as contact with Toxoplasma oocysts or tissue cysts seem to play a
decisive role in the process of infection.
Another hypothesis anticipated a signiﬁcant increase or
decrease in crucial parameters of the immune response after
seroconversion as a reaction to Toxoplasma infection. We found a
signiﬁcant increase in CD4 stimulated by Toxoplasma infection.
This change was not related to the introduction of cART or to a
change of treatment regimen before seroconversion. Thus, the
reason for this mild CD4 count increase remains unclear. A possible
explanation might be a partial restoration of the immune system
after development of the immune response against Toxoplasma
and the establishment of a latent infection. On the other hand, the
incidence of Toxoplasma seropositivity was previously found to be
higher in HIV-infected persons with CD4 counts of 200–499 cells/
ml compared to counts of >500 cells/ml.29 Unlike the CD4 count,
other parameters remained unchanged after seroconversion.Only thanks to years of monitoring very sizeable cohorts of HIV-
infected patients did we manage to detect 14 cases of seroconver-
sion and acquire unique data allowing an insight into the dynamics
of the immunological and clinical parameters prior to and
following Toxoplasma infection. However, the conclusions of our
study are limited by the low incidence of seroconversions and the
irregular intervals and number of examinations with great
ﬂuctuations in values.
Primary T. gondii infection is a rare event in Czech adult HIV-
infected patients and its incidence is similar to the incidence of
primary T. gondii infection in pregnant women in the Czech
Republic and other Central European countries. Of course, the
incidence of T. gondii infection can be inﬂuenced by preventive
education of individuals at risk, but we assume that this factor did
not play a major role in our cohort, because our patients were not
speciﬁcally instructed on how to prevent T. gondii infection (e.g.,
sufﬁcient cooking of meat, washing vegetables, caution when
handling cat litter or soil).
The course of primary T. gondii infection is usually asymptom-
atic in HIV-infected individuals, regardless of their immune status,
and can only be detected by regular serological screening. The
primary T. gondii infection itself does obviously not present a
signiﬁcant risk to the health of HIV-infected patients. It is of course
always valuable to recommend measures to patients to reduce the
risk of exposure to T. gondii, but on the other hand it does not
necessarily ensure prevention of primary T. gondii infection by
chemoprophylaxis. Primary T. gondii infection, however, also
represents the beginning of a process which in individuals with
profound immunodeﬁciency may result in a life-threatening
reactivation of latent infection; it is therefore advisable to perform
periodic serological screening for T. gondii to detect this change in
the patient’s medical condition in a timely manner.
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